AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna

Pfizer

Over the past three months, some of the world's biggest pharmaceutical companies, including Pfizer (NYSE: PFE), Moderna (NASDAQ: MRNA), and AstraZeneca (NASDAQ: AZN), have seen double-digit declines in their stock prices.

Pfizer, AstraZeneca, and Moderna lost $67 billion in market value since April

While AstraZeneca's (AZN) late-stage study evaluating an experimental lung cancer treatment showed improvement in progression free survival, it did not meet the threshold for statistical significance in overall survival.

AstraZeneca (AZN) Down 9% on Mixed Lung Cancer Study Results

Following AstraZeneca PLC's (LSE:AZN) update on its new cancer drug, datopotamab deruxtecan (Dato-DXd), several brokers have weighed in, including Deutsche Bank downgrading its stance and UBS saying the press release was "quite vague". Shares in the largest company on the FTSE 100 dropped almost 8% at the start of the week, erasing £14bn of value from the company's market cap and sending the shares to a four-month low below 10,400p.

AstraZeneca rebounds as analysts mull 'hard to read' cancer drug update

AstraZeneca PLC (NASDAQ:AZN) is gapping lower today, after the biopharmaceutical name's lung cancer drug disappointed investors in a late-stage trial.

Biopharma Stock Gaps Lower After Trial Disappoints

AstraZeneca and Daiichi Sankyo reported mixed results Monday from a final-phase study of their lung cancer treatment, and AZN stock tumbled.

AstraZeneca Plummets, Sacrificing A Breakout, On Mixed Results In Lung Cancer Treatment

AstraZeneca's AZN, +1.02% AZN, -5.43% shares slumped 6% in premarket trade. The U.K. drugmaker said its datopotamab deruxtecan treatment showed positive results in patients with advanced non-small cell lung cancer in a clinical Phase 3 trial.

AstraZeneca shares slump after Phase 3 lung cancer drug study

Tesla

Tesla stock TSLA, +1.66% soared 6% in premarket trade after the electric vehicle maker reported a record number of deliveries in the second quarter.

Tesla shares rally on delivery numbers, AstraZeneca stock slumps on drug trial, and other stocks on the move

Shares in pharmaceutical giant AstraZeneca PLC (LSE:AZN) fell 4.4% in early trading, erasing £7.3bn from the company's market value. The drop comes amid investor concerns over the results of a high-profile study of its new cancer drug, datopotamab deruxtecan (Dato-DXd).

AstraZeneca sees £7bn wiped from its value as lung cancer results fall short of 'best-case scenario'

British drugmaker AstraZeneca said on Monday its anti-body drug for lung cancer had met two of its main goals in a late-stage trial.

AstraZeneca reports positive results in late-stage trial of lung cancer therapy

British drugmaker AstraZeneca on Wednesday announced it would invest $400 million to plant over 200 million trees by 2030 as part of its strategy for reducing carbon emissions in line with the Paris Agreement.

AstraZeneca to spend $400 mln to plant 200 mln trees, cut carbon footprint

CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--Expansion of AZ Forest for climate action and human health.

AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health

Dividend-paying pharma stocks frequently deliver market-beating returns on capital. AstraZeneca stock, for instance, has consistently trounced the broader markets over the past 10 years.

Is AstraZeneca a Top Stock to Buy Right Now?

AstraZeneca (AZN) reportedly plans to spin-off its China business and list it separately in Hong Kong to protect itself from rising tensions between the United States and China.

AstraZeneca (AZN) May Reportedly Spin-Off its Chinese Business

AstraZeneca plc (LON: AZN) is considering spinning off its business in China, the Financial Times reported on Monday. Listing in Shanghai or Hong Kong also possible The pharmaceutical behemoth could restructure its operations in the said region and list them as a separate legal entity in Shanghai or Hong Kong, the daily business newspaper added.

AstraZeneca may soon spin off its business in China

UK's largest stock-market-listed firm weighs up Hong Kong or Shanghai listing to shield it from geopolitical tensions

AstraZeneca considers spinning off its China business

AstraZeneca PLC (LSE:AZN), the UK's largest listed company, is considering carving out its China business and listing it separately in Hong Kong, as a potential shield against escalating geopolitical tensions, according to the Financial Times. The Anglo-Swedish pharmaceutical giant is among a rising number of multinational corporations mulling over such strategic restructuring in response to growing friction between China, the US, and its allies, the paper said.

AstraZeneca reportedly mulling China spin-off

Drugmaker AstraZeneca is drafting a plan to spin off its China business, and listing a separate unit in Hong Kong is being viewed as an option, the Financial Times reported on Sunday.

AstraZeneca planning China business spin off, Financial Times reports

The FDA grants priority review status to AstraZeneca's (AZN) capivasertib/Faslodex combination for the treatment of adult patients with HR-positive, HER2-negative locally advanced breast cancer.

AstraZeneca (AZN) Breast Cancer Combo Drug Gets Priority Review

Pharmaceutical giant AstraZeneca will tap renewable natural gas made from cow manure and food waste to sharply reduce its carbon footprint at U.S. operations starting now and over the next few years, the company announced Tuesday.

AstraZeneca to decarbonize U.S. footprint by turning cow manure into renewable natural gas

Drugmaker AstraZeneca is switching to biogas produced from cow manure and food waste in the United States, it said on Tuesday, in a deal to cut its carbon emissions there.

AstraZeneca turns to cows to cut U.S. carbon footprint

WILMINGTON, Del.--(BUSINESS WIRE)--In a first-of-its-kind collaboration, AstraZeneca is partnering with Vanguard Renewables to deliver renewable natural gas to all its U.S. sites.

AstraZeneca announces innovative partnership with Vanguard Renewables to decarbonize its United States sites

AstraZeneca (AZN) enters into a collaboration agreement with Quell Therapeutics to co-develop novel cell therapy options in major autoimmune indications for an upfront payment of $85 million.

AstraZeneca (AZN) & Quell to Co-Develop Autoimmune Cell Therapies

The FDA's AMDAC unanimously recommends AstraZeneca (AZN)/Sanofi's (SNY) nirsevimab as full immunization against RSV disease for all infants.

FDA Panel Endorses AstraZeneca (AZN), Sanofi's RSV Antibody

AstraZeneca said on Friday it had signed an agreement with Quell Therapeutics potentially worth more than $2 billion to develop cell therapies that could cure autoimmune diseases.

AstraZeneca signs $2 bln agreement with Quell to develop cell therapies

AstraZeneca PLC (LSE:AZN) is placing an $85 million bet on the autoimmune cell therapy sector with Quell Therapeutics - its latest licensing partner. As well as a promising single treatment 'cure' for Type-1 diabetes, Quell is also working on drugs for inflammatory bowel disease.

News for AstraZeneca Stock (AZN)